Update on the Pathogenesis, Virulence, and Treatment of Candida auris
Article Sidebar
Main Article Content
Abstract
Candida auris is an emerging, multi-drug resistant fungal pathogen that causes considerable morbidity and mortality. First identified in Japan in 2009, it has since been reported in more than 40 countries. C. auris can persist for long periods on different environmental surfaces as well as the skin. Clinical isolates are typically resistant to commonly prescribed antifungal drugs. Increasingly recognized as a cause of infections and outbreaks in nosocomial settings, C. auris is difficult to identify using traditional microbiological methods. One of the main reasons for the ongoing spread of C. auris is the multitude of virulence factors it possesses and uses against its human host that enables fungal persistence on the skin surface. Yet, many of the virulence mechanisms are unknown or remain incompletely understood. In this review, we summarize the evolution of virulence of C. auris, offer recommendations for combating this important human pathogen, and suggest directions for further research.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41-4. doi: 10.1111/j.1348-0421.2008.00083.x. PubMed PMID: 19161556.
2. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. doi: 10.15620/cdc:82532. Available from: https://stacks.cdc.gov/view/cdc/82532.
3. Allert S, Schulz D, Kammer P, Grossmann P, Wolf T, Schauble S, Panagiotou G, Brunke S, Hube B. From environmental adaptation to host survival: Attributes that mediate pathogenicity of Candida auris. Virulence. 2022;13(1):191-214. doi: 10.1080/21505594.2022.2026037. PubMed PMID: 35142597; PMCID: PMC8837256.
4. Chow NA, Munoz JF, Gade L, Berkow EL, Li X, Welsh RM, Forsberg K, Lockhart SR, Adam R, Alanio A, Alastruey-Izquierdo A, Althawadi S, Arauz AB, Ben-Ami R, Bharat A, Calvo B, Desnos-Ollivier M, Escandon P, Gardam D, Gunturu R, Heath CH, Kurzai O, Martin R, Litvintseva AP, Cuomo CA. Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses. mBio. 2020;11(2):e03364-19. doi: 10.1128/mBio.03364-19. PubMed PMID: 32345637; PMCID: PMC7188998.
5. Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, Maor Y, Tarabia J, Schechner V, Adler A, Finn T. Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23(1):195-203. doi: 10.3201/eid2302.161486. PubMed PMID: 28098529; PMCID: PMC5324804.
6. Mohsin J, Weerakoon S, Ahmed S, Puts Y, Al Balushi Z, Meis JF, Al-Hatmi AMS. A Cluster of Candida auris Blood Stream Infections in a Tertiary Care Hospital in Oman from 2016 to 2019. Antibiotics (Basel). 2020;9(10):638. doi: 10.3390/antibiotics9100638. PubMed PMID: 32987692; PMCID: PMC7598619.
7. Casadevall A, Kontoyiannis DP, Robert V. Environmental Candida auris and the Global Warming Emergence Hypothesis. mBio. 2021;12(2):e00360-21. doi: 10.1128/mBio.00360-21. PubMed PMID: 33727350; PMCID: PMC8092241.
8. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, Jang HC. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49(9):3139-42. doi: 10.1128/JCM.00319-11. PubMed PMID: 21715586; PMCID: PMC3165631.
9. Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13(5):e1006290. doi: 10.1371/journal.ppat.1006290. PubMed PMID: 28542486; PMCID: PMC5436850.
10. Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, Hewitt C, Simner PJ, Carroll KC, Hayden RT, Zhang SX. Can Multidrug-Resistant Candida auris Be Reliably Identified in Clinical Microbiology Laboratories? J Clin Microbiol. 2017;55(2):638-40. doi: 10.1128/JCM.02202-16. PubMed PMID: 27881617; PMCID: PMC5277535.
11. Girard V, Mailler S, Chetry M, Vidal C, Durand G, van Belkum A, Colombo AL, Hagen F, Meis JF, Chowdhary A. Identification and typing of the emerging pathogen Candida auris by matrix-assisted laser desorption ionisation time of flight mass spectrometry. Mycoses. 2016;59(8):535-8. doi: 10.1111/myc.12519. PubMed PMID: 27292939.
12. Tamura T, Alshahni MM, Makimura K. Evaluation of CHROMagar Candida Plus chromogenic agar for the presumptive identification of Candida auris. Microbiol Immunol. 2022;66(6):292-8. doi: 10.1111/1348-0421.12973. PubMed PMID: 35229341.
13. Das S, Singh S, Tawde Y, Chakrabarti A, Rudramurthy SM, Kaur H, Shankarnarayan SA, Ghosh A. A Selective Medium for Isolation and Detection of Candida auris, an Emerging Pathogen. J Clin Microbiol. 2021;59(2):e00326-20. doi: 10.1128/JCM.00326-20. PubMed PMID: 33208474; PMCID: PMC8111121.
14. Lockhart SR, Lyman MM, Sexton DJ. Tools for Detecting a “Superbug”: Updates on Candida auris Testing. J Clin Microbiol. 2022;60(5):e0080821. doi: 10.1128/jcm.00808-21. PubMed PMID: 34985980; PMCID: PMC9116168.
15. Pezzotti G, Kobara M, Asai T, Nakaya T, Miyamoto N, Adachi T, Yamamoto T, Kanamura N, Ohgitani E, Marin E, Zhu W, Nishimura I, Mazda O, Nakata T, Makimura K. Raman Imaging of Pathogenic Candida auris: Visualization of Structural Characteristics and Machine-Learning Identification. Front Microbiol. 2021;12:769597. doi: 10.3389/fmicb.2021.769597. PubMed PMID: 34867902; PMCID: PMC8633489.
16. Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, Tarai B, Singh A, Upadhyaya G, Upadhyay S, Yadav P, Singh PK, Khillan V, Sachdeva N, Perlin DS, Meis JF. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73(4):891-9. doi: 10.1093/jac/dkx480. PubMed PMID: 29325167.
17. Hager CL, Larkin EL, Long L, Zohra Abidi F, Shaw KJ, Ghannoum MA. In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris. Antimicrob Agents Chemother. 2018;62(3):e02319-17. doi: 10.1128/AAC.02319-17. PubMed PMID: 29311065; PMCID: PMC5826120.
18. Ostrowsky B, Greenko J, Adams E, Quinn M, O’Brien B, Chaturvedi V, Berkow E, Vallabhaneni S, Forsberg K, Chaturvedi S, Lutterloh E, Blog D, Group CaIW. Candida auris Isolates Resistant to Three Classes of Antifungal Medications - New York, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(1):6-9. doi: 10.15585/mmwr.mm6901a2. PubMed PMID: 31917780; PMCID: PMC6973342.
19. Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6:69. doi: 10.1186/s40560-018-0342-4. PubMed PMID: 30397481; PMCID: PMC6206635.
20. Chowdhary A, Voss A, Meis JF. Multidrug-resistant Candida auris: ‘new kid on the block’ in hospital-associated infections? J Hosp Infect. 2016;94(3):209-12. doi: 10.1016/j.jhin.2016.08.004. PubMed PMID: 27634564.
21. Janniger EJ, Kapila R. Public health issues with Candida auris in COVID-19 patients. World Med Health Policy. 2021;13(4):766-72. doi: 10.1002/wmh3.472. PubMed PMID: 34909239; PMCID: PMC8661744.
22. Thoma R, Seneghini M, Seiffert SN, Vuichard Gysin D, Scanferla G, Haller S, Flury D, Boggian K, Kleger GR, Filipovic M, Nolte O, Schlegel M, Kohler P. The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature. Antimicrob Resist Infect Control. 2022;11(1):12. doi: 10.1186/s13756-022-01052-8. PubMed PMID: 35063032; PMCID: PMC8777447.
23. Kariyawasam RM, Julien DA, Jelinski DC, Larose SL, Rennert-May E, Conly JM, Dingle TC, Chen JZ, Tyrrell GJ, Ronksley PE, Barkema HW. Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021). Antimicrob Resist Infect Control. 2022;11(1):45. doi: 10.1186/s13756-022-01085-z. PubMed PMID: 35255988; PMCID: PMC8899460.
24. Yadav A, Singh A, Wang Y, Haren MHv, Singh A, de Groot T, Meis JF, Xu J, Chowdhary A. Colonisation and Transmission Dynamics of Candida auris among Chronic Respiratory Diseases Patients Hospitalised in a Chest Hospital, Delhi, India: A Comparative Analysis of Whole Genome Sequencing and Microsatellite Typing. Journal of Fungi. 2021;7(2):81. PubMed PMID: doi: 10.3390/jof7020081.
25. Pandya N, Cag Y, Pandak N, Pekok AU, Poojary A, Ayoade F, Fasciana T, Giammanco A, Caskurlu H, Rajani DP, Gupta YK, Balkan, II, Khan EA, Erdem H. International Multicentre Study of Candida auris Infections. J Fungi (Basel). 2021;7(10):878. doi: 10.3390/jof7100878. PubMed PMID: 34682299; PMCID: PMC8539607.
26. Ferrer Gomez C, Solis Albamonte P, Delgado Navarro C, Salvador Garcia C, Tormo Palop N, Andres Ibanez JA. Analysis of Candida auris candidemia cases in an Intensive Care Unit of a tertiary hospital. Rev Esp Anestesiol Reanim (Engl Ed). 2021;68(8):431-6. doi: 10.1016/j.redare.2020.10.006. PubMed PMID: 34538766.
27. Garcia-Bustos V, Salavert M, Ruiz-Gaitan AC, Cabanero-Navalon MD, Sigona-Giangreco IA, Peman J. A clinical predictive model of candidaemia by Candida auris in previously colonized critically ill patients. Clin Microbiol Infect. 2020;26(11):1507-13. doi: 10.1016/j.cmi.2020.02.001. PubMed PMID: 32061792.
28. Huang X, Welsh RM, Deming C, Proctor DM, Thomas PJ, Program NCS, Gussin GM, Huang SS, Kong HH, Bentz ML, Vallabhaneni S, Chiller T, Jackson BR, Forsberg K, Conlan S, Litvintseva AP, Segre JA. Skin Metagenomic Sequence Analysis of Early Candida auris Outbreaks in U.S. Nursing Homes. mSphere. 2021;6(4):e0028721. doi: 10.1128/mSphere.00287-21. PubMed PMID: 34346704; PMCID: PMC8386442.
29. Yang YL. Virulence factors of Candida species. J Microbiol Immunol Infect. 2003;36(4):223-8. PubMed PMID: 14723249.
30. Saporito-Irwin SM, Birse CE, Sypherd PS, Fonzi WA. PHR1, a pH-regulated gene of Candida albicans, is required for morphogenesis. Mol Cell Biol. 1995;15(2):601-13. doi: 10.1128/MCB.15.2.601. PubMed PMID: 7823929; PMCID: PMC231914.
31. Heinz WJ, Kurzai O, Brakhage AA, Fonzi WA, Korting H-C, Frosch M, Mühlschlegel FA. Molecular responses to changes in the environmental pH are conserved between the fungal pathogens Candida dubliniensis and Candida albicans. International Journal of Medical Microbiology. 2000;290(3):231-8. doi: 10.1016/s1438-4221(00)80120-4.
32. Thompson DS, Carlisle PL, Kadosh D. Coevolution of morphology and virulence in Candida species. Eukaryot Cell. 2011;10(9):1173-82. doi: 10.1128/EC.05085-11. PubMed PMID: 21764907; PMCID: PMC3187052.
33. Sherry L, Ramage G, Kean R, Borman A, Johnson EM, Richardson MD, Rautemaa-Richardson R. Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris. Emerg Infect Dis. 2017;23(2):328-31. doi: 10.3201/eid2302.161320. PubMed PMID: 28098553; PMCID: PMC5324806.
34. Munoz JF, Gade L, Chow NA, Loparev VN, Juieng P, Berkow EL, Farrer RA, Litvintseva AP, Cuomo CA. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun. 2018;9(1):5346. doi: 10.1038/s41467-018-07779-6. PubMed PMID: 30559369; PMCID: PMC6297351.
35. de Jong AW, Hagen F. Attack, Defend and Persist: How the Fungal Pathogen Candida auris was Able to Emerge Globally in Healthcare Environments. Mycopathologia. 2019;184(3):353-65. doi: 10.1007/s11046-019-00351-w. PubMed PMID: 31209693.
36. Rapala-Kozik M, Bochenska O, Zajac D, Karkowska-Kuleta J, Gogol M, Zawrotniak M, Kozik A. Extracellular proteinases of Candida species pathogenic yeasts. Mol Oral Microbiol. 2018;33(2):113-24. doi: 10.1111/omi.12206. PubMed PMID: 29139623.
37. Lee SA, Jones J, Hardison S, Kot J, Khalique Z, Bernardo SM, Lazzell A, Monteagudo C, Lopez-Ribot J. Candida albicans VPS4 is required for secretion of aspartyl proteases and in vivo virulence. Mycopathologia. 2009;167(2):55-63. doi: 10.1007/s11046-008-9155-7. PubMed PMID: 18814053; PMCID: PMC5898969.
38. Chatterjee S, Alampalli SV, Nageshan RK, Chettiar ST, Joshi S, Tatu US. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics. 2015;16(1):686. doi: 10.1186/s12864-015-1863-z. PubMed PMID: 26346253; PMCID: PMC4562351.
39. Wang X, Bing J, Zheng Q, Zhang F, Liu J, Yue H, Tao L, Du H, Wang Y, Wang H, Huang G. The first isolate of Candida auris in China: clinical and biological aspects. Emerg Microbes Infect. 2018;7(1):93. doi: 10.1038/s41426-018-0095-0. PubMed PMID: 29777096; PMCID: PMC5959928.
40. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev. 2000;13(1):122-43, table of contents. doi: 10.1128/CMR.13.1.122. PubMed PMID: 10627494; PMCID: PMC88936.
41. Gacser A, Trofa D, Schafer W, Nosanchuk JD. Targeted gene deletion in Candida parapsilosis demonstrates the role of secreted lipase in virulence. J Clin Invest. 2007;117(10):3049-58. doi: 10.1172/JCI32294. PubMed PMID: 17853941; PMCID: PMC1974868.
42. Trofa D, Soghier L, Long C, Nosanchuk JD, Gacser A, Goldman DL. A rat model of neonatal candidiasis demonstrates the importance of lipases as virulence factors for Candida albicans and Candida parapsilosis. Mycopathologia. 2011;172(3):169-78. doi: 10.1007/s11046-011-9429-3. PubMed PMID: 21667319.
43. Larkin E, Hager C, Chandra J, Mukherjee PK, Retuerto M, Salem I, Long L, Isham N, Kovanda L, Borroto-Esoda K, Wring S, Angulo D, Ghannoum M. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrob Agents Chemother. 2017;61(5):e02396-16. doi: 10.1128/AAC.02396-16. PubMed PMID: 28223375; PMCID: PMC5404565.
44. Kean R, Delaney C, Sherry L, Borman A, Johnson EM, Richardson MD, Rautemaa-Richardson R, Williams C, Ramage G. Transcriptome Assembly and Profiling of Candida auris Reveals Novel Insights into Biofilm-Mediated Resistance. mSphere. 2018;3(4):e00334-18. doi: 10.1128/mSphere.00334-18. PubMed PMID: 29997121; PMCID: PMC6041501.
45. Johnson CJ, Davis JM, Huttenlocher A, Kernien JF, Nett JE. Emerging Fungal Pathogen Candida auris Evades Neutrophil Attack. mBio. 2018;9(4). doi: 10.1128/mBio.01403-18. PubMed PMID: 30131360; PMCID: PMC6106086.
46. Wurster S, Bandi A, Beyda ND, Albert ND, Raman NM, Raad, II, Kontoyiannis DP. Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris. J Antimicrob Chemother. 2019;74(7):1904-10. doi: 10.1093/jac/dkz100. PubMed PMID: 31225606; PMCID: PMC7967830.
47. Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X. Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019;17:661-74. doi: 10.1016/j.csbj.2019.03.006. PubMed PMID: 31205619; PMCID: PMC6558092.
48. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J, Palmore TN, Zelzany A, Adams EH, Quinn M, Chaturvedi S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Msd, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J, Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, Chiller TM. Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016. MMWR Morb Mortal Wkly Rep. 2016;65(44):1234-7. doi: 10.15585/mmwr.mm6544e1. PubMed PMID: 27832049.
49. Wang Y, Xu J. Population genomic analyses reveal evidence for limited recombination in the superbug Candida auris in nature. Comput Struct Biotechnol J. 2022;20:3030-40. doi: 10.1016/j.csbj.2022.06.030. PubMed PMID: 35782746; PMCID: PMC9218166.
50. Bravo Ruiz G, Lorenz A. What do we know about the biology of the emerging fungal pathogen of humans Candida auris? Microbiol Res. 2021;242:126621. doi: 10.1016/j.micres.2020.126621. PubMed PMID: 33096325.
51. Chybowska AD, Childers DS, Farrer RA. Nine Things Genomics Can Tell Us About Candida auris. Front Genet. 2020;11:351. doi: 10.3389/fgene.2020.00351. PubMed PMID: 32351544; PMCID: PMC7174702.
52. Kumar D, Banerjee T, Pratap CB, Tilak R. Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. J Infect Dev Ctries. 2015;9(4):435-7. doi: 10.3855/jidc.4582. PubMed PMID: 25881537.
53. Kean R, Ramage G. Combined Antifungal Resistance and Biofilm Tolerance: the Global Threat of Candida auris. mSphere. 2019;4(4):e00458-19. doi: 10.1128/mSphere.00458-19. PubMed PMID: 31366705; PMCID: PMC6669339.
54. Kumar J, Eilertson B, Cadnum JL, Whitlow CS, Jencson AL, Safdar N, Krein SL, Tanner WD, Mayer J, Samore MH, Donskey CJ. Environmental Contamination with Candida Species in Multiple Hospitals Including a Tertiary Care Hospital with a Candida auris Outbreak. Pathog Immun. 2019;4(2):260-70. doi: 10.20411/pai.v4i2.291. PubMed PMID: 31768483; PMCID: PMC6827507.
55. Ledwoch K, Maillard J-Y. Candida auris Dry Surface Biofilm (DSB) for Disinfectant Efficacy Testing. Materials. 2019;12(1):18. PubMed PMID: doi: 10.3390/ma12010018.
56. Cadnum JL, Shaikh AA, Piedrahita CT, Sankar T, Jencson AL, Larkin EL, Ghannoum MA, Donskey CJ. Effectiveness of Disinfectants Against Candida auris and Other Candida Species. Infect Control Hosp Epidemiol. 2017;38(10):1240-3. doi: 10.1017/ice.2017.162. PubMed PMID: 28793937.
57. Bapat PS, Nobile CJ. Photodynamic Therapy Is Effective Against Candida auris Biofilms. Front Cell Infect Microbiol. 2021;11:713092. doi: 10.3389/fcimb.2021.713092. PubMed PMID: 34540717; PMCID: PMC8446617.
58. Cadnum JL, Shaikh AA, Piedrahita CT, Jencson AL, Larkin EL, Ghannoum MA, Donskey CJ. Relative Resistance of the Emerging Fungal Pathogen Candida auris and Other Candida Species to Killing by Ultraviolet Light. Infect Control Hosp Epidemiol. 2018;39(1):94-6. doi: 10.1017/ice.2017.239. PubMed PMID: 29157326.
59. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol. 1996;34(3):489-95. doi: 10.1128/jcm.34.3.489-495.1996. PubMed PMID: 8904400; PMCID: PMC228832.
60. Ghannoum M, Isham N, Angulo D, Borroto-Esoda K, Barat S, Long L. Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model. Antimicrob Agents Chemother. 2020;64(10):e00854-20. doi: 10.1128/AAC.00854-20. PubMed PMID: 32718958; PMCID: PMC7508588.
61. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008;46(8):2620-9. doi: 10.1128/JCM.00566-08. PubMed PMID: 18579718; PMCID: PMC2519503.
62. Huang X, Hurabielle C, Drummond RA, Bouladoux N, Desai JV, Sim CK, Belkaid Y, Lionakis MS, Segre JA. Murine model of colonization with fungal pathogen Candida auris to explore skin tropism, host risk factors and therapeutic strategies. Cell Host Microbe. 2021;29(2):210-21 e6. doi: 10.1016/j.chom.2020.12.002. PubMed PMID: 33385336; PMCID: PMC7878403.
63. Fakhim H, Vaezi A, Dannaoui E, Chowdhary A, Nasiry D, Faeli L, Meis JF, Badali H. Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model. Mycoses. 2018;61(6):377-82. doi: 10.1111/myc.12754. PubMed PMID: 29460345.
64. Lionakis MS, Kontoyiannis DP. The growing promise of Toll-deficient Drosophila melanogaster as a model for studying Aspergillus pathogenesis and treatment. Virulence. 2010;1(6):488-99. doi: 10.4161/viru.1.6.13311. PubMed PMID: 21178494; PMCID: PMC3073358.
65. Chaabane F, Graf A, Jequier L, Coste AT. Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris. Front Microbiol. 2019;10:2788. doi: 10.3389/fmicb.2019.02788. PubMed PMID: 31849919; PMCID: PMC6896226.
66. Rybak JM, Doorley LA, Nishimoto AT, Barker KS, Palmer GE, Rogers PD. Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of Candida auris. Antimicrob Agents Chemother. 2019;63(4):e00057-19. doi: 10.1128/AAC.00057-19. PubMed PMID: 30718246; PMCID: PMC6437491.
67. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother. 1998;42(2):241-53. doi: 10.1128/AAC.42.2.241. PubMed PMID: 9527767; PMCID: PMC105395.
68. Healey KR, Kordalewska M, Jimenez Ortigosa C, Singh A, Berrio I, Chowdhary A, Perlin DS. Limited ERG11 Mutations Identified in Isolates of Candida auris Directly Contribute to Reduced Azole Susceptibility. Antimicrob Agents Chemother. 2018;62(10):e01427-18. doi: 10.1128/AAC.01427-18. PubMed PMID: 30082281; PMCID: PMC6153782.
69. Martins IM, Cortes JC, Munoz J, Moreno MB, Ramos M, Clemente-Ramos JA, Duran A, Ribas JC. Differential activities of three families of specific beta(1,3)glucan synthase inhibitors in wild-type and resistant strains of fission yeast. J Biol Chem. 2011;286(5):3484-96. doi: 10.1074/jbc.M110.174300. PubMed PMID: 21115488; PMCID: PMC3030354.
70. Dominguez EG, Zarnowski R, Choy HL, Zhao M, Sanchez H, Nett JE, Andes DR. Conserved Role for Biofilm Matrix Polysaccharides in Candida auris Drug Resistance. mSphere. 2019;4(1):e00680-18. doi: 10.1128/mSphereDirect.00680-18. PubMed PMID: 30602527; PMCID: PMC6315084.
71. Maphanga TG, Naicker SD, Kwenda S, Munoz JF, van Schalkwyk E, Wadula J, Nana T, Ismail A, Coetzee J, Govind C, Mtshali PS, Mpembe RS, Govender NP, for G-S. In Vitro Antifungal Resistance of Candida auris Isolates from Bloodstream Infections, South Africa. Antimicrob Agents Chemother. 2021;65(9):e0051721. doi: 10.1128/AAC.00517-21. PubMed PMID: 34228535; PMCID: PMC8370198.
72. Aghaei Gharehbolagh S, Izadi A, Talebi M, Sadeghi F, Zarrinnia A, Zarei F, Darmiani K, Borman AM, Mahmoudi S. New weapons to fight a new enemy: A systematic review of drug combinations against the drug-resistant fungus Candida auris. Mycoses. 2021;64(11):1308-16. doi: 10.1111/myc.13277. PubMed PMID: 33774879.
73. Jallow S, Govender NP. Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor. J Fungi (Basel). 2021;7(3):163. doi: 10.3390/jof7030163. PubMed PMID: 33668824; PMCID: PMC7996284.
74. Ghannoum M, Long L, Larkin EL, Isham N, Sherif R, Borroto-Esoda K, Barat S, Angulo D. Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis. Antimicrob Agents Chemother. 2018;62(6):e00244-18. doi: 10.1128/AAC.00244-18. PubMed PMID: 29610204; PMCID: PMC5971594.